|
Gene: AP3M2 |
Gene summary for AP3M2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | AP3M2 | Gene ID | 10947 |
Gene name | adaptor related protein complex 3 subunit mu 2 | |
Gene Alias | AP47B | |
Cytomap | 8p11.21 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P53677 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10947 | AP3M2 | LZE4T | Human | Esophagus | ESCC | 1.68e-05 | 2.37e-01 | 0.0811 |
10947 | AP3M2 | LZE7T | Human | Esophagus | ESCC | 2.34e-02 | 2.16e-01 | 0.0667 |
10947 | AP3M2 | LZE20T | Human | Esophagus | ESCC | 2.42e-04 | 2.77e-01 | 0.0662 |
10947 | AP3M2 | LZE24T | Human | Esophagus | ESCC | 7.36e-08 | 2.96e-01 | 0.0596 |
10947 | AP3M2 | P2T-E | Human | Esophagus | ESCC | 8.73e-28 | 4.47e-01 | 0.1177 |
10947 | AP3M2 | P4T-E | Human | Esophagus | ESCC | 9.80e-17 | 4.00e-01 | 0.1323 |
10947 | AP3M2 | P5T-E | Human | Esophagus | ESCC | 1.88e-04 | 9.86e-02 | 0.1327 |
10947 | AP3M2 | P8T-E | Human | Esophagus | ESCC | 3.75e-03 | 8.66e-02 | 0.0889 |
10947 | AP3M2 | P9T-E | Human | Esophagus | ESCC | 2.46e-02 | 1.00e-01 | 0.1131 |
10947 | AP3M2 | P10T-E | Human | Esophagus | ESCC | 2.20e-17 | 2.91e-01 | 0.116 |
10947 | AP3M2 | P11T-E | Human | Esophagus | ESCC | 3.47e-03 | 2.07e-01 | 0.1426 |
10947 | AP3M2 | P12T-E | Human | Esophagus | ESCC | 5.00e-17 | 2.74e-01 | 0.1122 |
10947 | AP3M2 | P15T-E | Human | Esophagus | ESCC | 4.83e-17 | 4.43e-01 | 0.1149 |
10947 | AP3M2 | P16T-E | Human | Esophagus | ESCC | 1.73e-78 | 1.36e+00 | 0.1153 |
10947 | AP3M2 | P17T-E | Human | Esophagus | ESCC | 5.74e-03 | 1.59e-01 | 0.1278 |
10947 | AP3M2 | P19T-E | Human | Esophagus | ESCC | 4.87e-02 | 2.67e-01 | 0.1662 |
10947 | AP3M2 | P20T-E | Human | Esophagus | ESCC | 3.31e-12 | 2.87e-01 | 0.1124 |
10947 | AP3M2 | P21T-E | Human | Esophagus | ESCC | 3.89e-12 | 2.09e-01 | 0.1617 |
10947 | AP3M2 | P22T-E | Human | Esophagus | ESCC | 9.74e-22 | 3.85e-01 | 0.1236 |
10947 | AP3M2 | P23T-E | Human | Esophagus | ESCC | 3.30e-26 | 6.42e-01 | 0.108 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
GO:00723846 | Esophagus | ESCC | organelle transport along microtubule | 65/8552 | 85/18723 | 6.61e-09 | 1.35e-07 | 65 |
GO:000808810 | Esophagus | ESCC | axo-dendritic transport | 58/8552 | 75/18723 | 2.09e-08 | 4.02e-07 | 58 |
GO:00989304 | Esophagus | ESCC | axonal transport | 49/8552 | 64/18723 | 4.54e-07 | 6.15e-06 | 49 |
GO:00474962 | Esophagus | ESCC | vesicle transport along microtubule | 36/8552 | 47/18723 | 1.53e-05 | 1.38e-04 | 36 |
GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
GO:00080892 | Esophagus | ESCC | anterograde axonal transport | 37/8552 | 50/18723 | 4.42e-05 | 3.51e-04 | 37 |
GO:00995185 | Esophagus | ESCC | vesicle cytoskeletal trafficking | 50/8552 | 73/18723 | 6.75e-05 | 5.12e-04 | 50 |
GO:00484901 | Esophagus | ESCC | anterograde synaptic vesicle transport | 15/8552 | 19/18723 | 3.29e-03 | 1.35e-02 | 15 |
GO:00995141 | Esophagus | ESCC | synaptic vesicle cytoskeletal transport | 15/8552 | 19/18723 | 3.29e-03 | 1.35e-02 | 15 |
GO:00995171 | Esophagus | ESCC | synaptic vesicle transport along microtubule | 15/8552 | 19/18723 | 3.29e-03 | 1.35e-02 | 15 |
GO:00484892 | Esophagus | ESCC | synaptic vesicle transport | 28/8552 | 42/18723 | 4.90e-03 | 1.89e-02 | 28 |
GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
GO:005165021 | Liver | HCC | establishment of vesicle localization | 103/7958 | 161/18723 | 2.94e-08 | 6.69e-07 | 103 |
GO:005164821 | Liver | HCC | vesicle localization | 107/7958 | 177/18723 | 1.05e-06 | 1.57e-05 | 107 |
GO:00080882 | Liver | HCC | axo-dendritic transport | 52/7958 | 75/18723 | 2.34e-06 | 3.14e-05 | 52 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AP3M2 | SNV | Missense_Mutation | c.73A>G | p.Ser25Gly | p.S25G | P53677 | protein_coding | tolerated(0.33) | benign(0.049) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | ||
AP3M2 | SNV | Missense_Mutation | novel | c.1184N>G | p.Tyr395Cys | p.Y395C | P53677 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-D8-A73X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
AP3M2 | insertion | Nonsense_Mutation | novel | c.265_266insTTTGATGCTCAATCCCACTTCCATGTATGAAAAAATACGGTC | p.Thr89delinsIleTerCysSerIleProLeuProCysMetLysLysTyrGlyPro | p.T89delinsI*CSIPLPCMKKYGP | P53677 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
AP3M2 | insertion | Frame_Shift_Ins | novel | c.255_256insTCTGCCCGCGGAGGCCTCCCTAAGTACTGGGATCACAGGC | p.Val86SerfsTer39 | p.V86Sfs*39 | P53677 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
AP3M2 | insertion | Frame_Shift_Ins | novel | c.174_175insCTCGCTG | p.Val59LeufsTer25 | p.V59Lfs*25 | P53677 | protein_coding | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
AP3M2 | insertion | Nonsense_Mutation | novel | c.176_177insCCCATAGTGGCTATCGTATTAAGCTGCGCA | p.Val59_Tyr60insProTerTrpLeuSerTyrTerAlaAlaHis | p.V59_Y60insP*WLSY*AAH | P53677 | protein_coding | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
AP3M2 | SNV | Missense_Mutation | rs151272027 | c.722G>A | p.Arg241His | p.R241H | P53677 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AP3M2 | SNV | Missense_Mutation | rs151272027 | c.722N>A | p.Arg241His | p.R241H | P53677 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
AP3M2 | SNV | Missense_Mutation | c.32C>T | p.Ser11Phe | p.S11F | P53677 | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-AA-3712-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
AP3M2 | SNV | Missense_Mutation | novel | c.712N>T | p.Arg238Cys | p.R238C | P53677 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |